Comparative Pharmacology
Head-to-head clinical analysis: BROMPHERIL versus PROMETHAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMPHERIL versus PROMETHAZINE HYDROCHLORIDE.
BROMPHERIL vs PROMETHAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brompheril is a mu-opioid receptor agonist with additional sigma-1 receptor antagonism, producing analgesic effects and modulating neuropathic pain.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, blocking the effects of histamine at H1 receptors. It also has anticholinergic, antiemetic, sedative, and antidopaminergic properties.
In adults, the usual dose is 1-2 mg/kg intravenously every 4-6 hours as needed. Alternatively, 5 mg can be administered intramuscularly or subcutaneously every 4 hours.
25-50 mg intramuscular or intravenous injection every 4-6 hours as needed; also 12.5-25 mg orally every 4-6 hours.
None Documented
None Documented
Terminal half-life 2.5-4 hours; prolonged in renal impairment (up to 12 hours in severe cases).
Terminal elimination half-life is 10-19 hours in adults; prolonged in hepatic impairment (up to 30+ hours) and in elderly.
Primarily renal (60-70% as unchanged drug); 15-20% fecal via biliary elimination; minor metabolic clearance.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <1% of unchanged drug; biliary/fecal excretion of metabolites ~70-80%.
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic